Patent ID: 7384954

Claim:
A compound according to formula I: wherein: A represents: where R represents hydrogen or methyl, and R 1 represents hydrogen or a moiety of Formula VI wherein: Ar 1 is selected from a 5- or 6-membered aromatic or heteroaromatic ring having 0, 1 or 2 nitrogen atoms, 0 or 1 oxygen atoms, and 0 or 1 sulfur atoms, or selected from an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system having 0, 1, 2 or 3 nitrogen atoms, 0 or 1 oxygen atoms, and 0 or 1 sulfur atoms; D is selected from hydrogen, NR 2 R 3 , or E-Ar 2 ; wherein E is a single bond, —O—, —S—, or —NR 3 —; Ar 2 is selected from a 5- or 6-membered aromatic or heteroaromatic ring having 0, 1 or 2 nitrogen atoms, 0 or 1 oxygen atoms, and 0 or 1 sulfur atoms; where each Ar 1 or Ar 2 moiety may be unsubstituted or bear 1, 2 or 3 substituents selected from —R 3 , —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, halogen, —CN, —NO 2 , —CF 3 , —S(O) n R 3 , —NR 2 R 3 , —CH 2 NR 2 R 3 , —OR 3 , —CH 2 OR 3 or —CO 2 R 4 ; R 2 and R 3 are independently selected at each occurrence from hydrogen, —C 1 -C 4 alkyl, aryl, heteroaryl, —C(O)R 4 , —C(O)NHR 4 , —CO 2 R 4 or —SO 2 R 4 , or R 2 and R 3 in combination is —(CH 2 ) j G(CH 2 ) k — wherein G is oxygen, sulfur, NR 4 , or a bond; j is 2, 3 or 4; k is 0, 1 or 2; n is 0, 1 or 2, and R 4 is independently selected at each occurrence from hydrogen, —C 1-4 alkyl, aryl, or heteroaryl; and stereoisomers, enantiomers, in vivo-hydrolysable precursors and pharmaceutically-acceptable salts thereof.